enabling Regeneron to accelerate the development of innovative genetic therapies and a rich pipeline of hearing loss treatments," said George Yancopolous, Regeneron's chief scientific officer.

Regeneron’s chief scientific officer, George Yancopoulos, said: “We believe that the tremendous synergies between Regeneron’s proven technologies and bluebird’s toolbox of advanced cell ...